{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-083425","form_type":"8-K","ticker":"HEPA","cik":"0001583771","company_name":"Hepion Pharmaceuticals, Inc.","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.432621+00:00","generated_at":"2026-06-13T04:13:38.037553+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"medium","headline":"Hepion provides corporate presentation; no material new financial or clinical data","bullets":["Rencofilstat Phase 2b ASCEND-NASH enrolling; AI-POWR platform highlighted.","Phase 2a HCC trial pending; rencofilstat tested in over 425 subjects to date.","Cash of $43.0M as of March 31, 2023; IP extends to at least 2031 with PTE.","Core team previously developed voclosporin (Lupkynis) for lupus nephritis.","Presentation details pipeline, finance, and management; no new clinical results disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-083425","json":"https://secwatch.observer/filing/0001104659-23-083425.json","markdown":"https://secwatch.observer/filing/0001104659-23-083425.md","text":"https://secwatch.observer/filing/0001104659-23-083425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923083425/0001104659-23-083425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583771/000110465923083425/tm2321697d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:13:38.037553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}